Company targets the US and Europe as global wait list for full body scanning technology reaches more than 100,000.
Swedish healthtech company Neko Health has raised a huge $260 million Series B funding round as it seeks to advance preventive health and early detection via its full body scanning technology. The company says the funding will fuel its expansion plans across Europe and the United States, alongside ongoing investments in research and development to discover breakthroughs in health diagnostics.
Co-founded by Spotify creator Daniel Ek and Hjalmar Nilsonne, Neko’s preventative approach aims to lay the groundwork for a future where early detection and prevention play a central role in health management. In under an hour, the company’s non-invasive health scan, priced at £299, captures millions of health data points, examining factors such as skin abnormalities, metabolic syndrome symptoms, stroke and heart attack risks, pre-diabetes indicators and signs of skin cancer or blood disorders. Results are immediately shared with patients during a doctor-led consultation.
The company released findings from 2,707 scans in its first year of operation. Among those scanned, 78.5% displayed no health issues requiring further examination, however, 14.1% of participants required medical intervention, and 1% received potentially life-saving interventions for severe conditions, such as cardiovascular diseases, metabolic disorders, and malignant melanomas.
“The greatest challenge in modern healthcare isn’t treating the sick – it’s engaging the healthy,” said Dr Vishal Gulati, independent health expert, and managing partner at Recode Ventures. “People don’t want to be patients; they want to be participants in their own wellbeing journey. Having experienced the Neko Health scan for myself, I’m even more convinced of the need to shift from a system that waits for sickness to one that empowers wellness through experiences like this.”
Neko says it has completed 10,000 scans in London and Stockholm, where its services are currently available, and claims significant patient loyalty, with 76% of participants opting to rebook for the following year. With a global waiting list exceeding 100,000 individuals, the company is actively scaling its capacity to meet the surging demand.
“We’re at the beginning of a big shift of the healthcare market, from reactive to proactive, driven both by technological advancements and growing consumer demand,” said Neko CEO Nilsonne. “This round of financing accelerates Neko’s global expansion of locations to include the US, as well as investments in breakthrough R&D. In the coming years Neko will continue to bring incredible innovations to the market to find and prevent disease before it has a chance to develop.”
The funding round, which follows Neko’s $65 million Series A, was led by Lightspeed Venture Partners, with participation from General Catalyst, OG Venture Partners, Rosello, Lakestar, and Atomico. As part of the funding round, Bejul Somaia, a Partner at Lightspeed Venture Partners, joins the company’s Board of Directors.
“After meeting Hjalmar, Daniel and their team, it was clear Neko Health wasn’t just building another healthcare company – they were fundamentally rethinking how we approach prevention,” said Somaia. “Neko combines breakthrough technology with meticulous attention to detail in everything from their scanning technology to the patient experience. With a long waitlist and a clear path to international expansion, we believe comprehensive preventive care can be both accessible and scalable.”
